Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

British Journal of Cancer

Volumn 82, Issue 3, 2000, Pages 560-567

  Paradiso, A ^a   Simone, G ^a   Petroni, S ^a   Leone, B ^b   Vallejo, C ^b   Lacava, J ^b   Romero, A ^b   Machiavelli, M ^b   De Lena, M ^a   Allegra, C J ^c   Johnston, P G ^d  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b Grupo Oncologico Cooperativo del Sur   (Argentina)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Colorectal cancer; p53; Predictive factor; Prognosis; TS

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

EID: 0033975032     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0964     Document Type: Article

References (42)

1. American Joint Committee on Cancer (1988) Manual for Staging of Cancer 3rd edn, p.7. Lippincott: Philadelphia
2. Bathasdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, Suthar TP, et al (1997) Coexpression of Bcl-2, c-myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40: 785-790
3. Bosari S and Viale G (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86: 681-687
4. Boyle P (1997) Global burden of cancer. Lancet 349: 23-26
5. Bulleco C, Guillem JG, Kemeney N, Huang Y, Klimistra D, Berger MF, et al (1996) p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14: 2696-2701
6. Chin KV, Ueda K, Pastran I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by RAS and p53. Science 255: 459-462
7. Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA, Yeh GC, et al (1990) Induction of thymidilate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136-143
8. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood BC, et al (1991) Autoregulation of human thymidilate messenger RNA translation by thymidilate synthase. Proc Natl Acad Sci USA 88: 8977-8981
9. Cook A and Milner J (1990) Evidence of allosteric variants for wild type p53, a tumour suppressor protein. Br J Cancer 61: 548-562
10. Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I and Ragnhammar P (1997) Immunohistochemical determination of thymidylate synthase in colorectal-cancer-methodological studies. Eur. J. Cancer 33: 2278-2282
11. Findlay MPN, Cunningham D, Morgan G and Clinton S (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy. Br J Cancer 75: 903-909
12. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
13. Hermeking H and Heick D (1994) Mediation of c-myc-induced apoptosis by p53. Science 265: 2091-2093
14. Isacoff WH and Borud K (1997) Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg 21: 748-762
15. Johnston PG, Liang CM, Henry S, Chabner BA and Allegra C (1991) Production and characterization of monoclonal antibodies that localise human thymidilate synthase in the cytoplasm of human cells and tissue. Cancer Res 51: 6668-6676
16. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al (1994) The role of thymidilate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647
17. Johnston PG, Lenz HJ, Leichman CG, Danenberg K, Allegra C, Danenberg PV, et al (1995) Thymidilate synthase gene and protein expression correlate and are associated with response to 5-Fluorouracil in human colorectal and gastric cancer. Cancer Res 55: 1407-1412
18. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, et al (1997) Thymidilate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89: 308-313
19. Kornmann M, Link KH, Lenz HJ, Pillasch J, Metzger R, Butzer U, et al (1997) Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion. Cancer Letter 118: 29-35
20. Larsson PA, Carlsson G, Gustavsson B and Spears PC (1996) Thymidilate synthase in advanced gastrointestinal and breast cancers. Acta Oncologica 35: 469-472
21. Lee Y, Chen Y, Chang LS and Johnson LF (1997) Inhibition of mouse thymidilate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 234: 270-276
22. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al (1997) Quantitation of intratumoral thymidilate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229
23. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger T, Banerijee D, Bertino JR, Groshen S, Leichman LP and Leichman CG (1998) p53 point mutations and Thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res. 4: 1243-1250
24. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810
25. Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, et al (1991) Advanced colorectal carcinoma. Am J Clin Oncol 14: 211-217
26. Machover D (1997) A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80: 1179-1187
27. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, et al (1997) Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74: 346-358
28. Merchant AK, Loney TL and Maybaum J (1996) Expression of wild-type p53 stimulates an increase in both Bax and Bcl-x(L) protein content in HT29 cells. Oncogene 13: 2631-2637
29. Mueller H and Eppenberger U (1996) The dual role of mutant p53 protein in chemosensitivity of human cancer. Anticancer Res 16: 3845-3848
30. Navalgund LG, Rossann C, Muench AJ and Johnson LF (1980) Cell cycle regulation of thymidilate synthase gene expression in culture mouse fibroblasts. J Biol Chem 255: 7386-7390
31. Paradiso A, Rabinovich M, Vallejo C, Machiavelli M, Romero A, Perez J, et al (1996) p53 and PCNA expression in advanced colorectal cancer. Response to chemotherapy and long-term prognosis. Int J Cancer 69: 437-441
32. Pestalozzi BC, McGinn CJ, Kinsella TJ, Drake JC, Glennon MC, Allegra CJ, et al (1995) Increased thymidilate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 71: 1151-1157
33. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, et al (1997) Prognostic importance of thymidilate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931
34. Peters GJ, Van Der Wilt CL, Van Groeningen CJ, Meijer S, Smid K and Pinedo HM (1994) Thymidilate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil. J Clin Oncol 12: 2035-2042
35. Peters GJ, Van Der Wilt CL, Van Triest B, Codacci-Pisanelli G, Johnston PG, Van Groeningen CJ, et al (1995) Thymidylate synthase and drug resistance. Eur J Cancer 31(7): 1299-1305
36. SEER Cancer Statistics Review, 1973-1993, preliminary edition (1997) Colorectal cancer incidence. J Natl. Cancer Inst 89: 416
37. Simes RJ and Zelen M (1985) Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's prime. J Clin Oncol 3: 1418-1431
38. Slebos RJC, Baas IO, Clement M, Polak M, Mulder JW, Van Den Berg FM, et al (1996) Clinical and pathological associations with p53 tumor-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 74: 165-171
39. Smith DR, Ji CY and Goh HS (1996) Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74: 216-223
40. Spears C (1995) Clinical resistance to antimetabolites. Haematol Oncol Clin North Am 9: 397-413
41. Spears CP, Shahanian AH and Moran RG (1982) In vivo kinetics of thymidilate synthase inhibition of 5-fluorouracil-sensitive and resistant murine colon adenocacarcinomas. Cancer Res 42: 450-456
42. Yang B, Eshleman JR, Berger NA and Markowitz SD (1996) Wild-type p53 potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2: 1649-1657